The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming ...
Hosted on MSN16d
FDA CDER director Patrizia Cavazzoni announces resignationFollowing a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...
It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.
Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a letter to the company. Enforcement discretion: The FDA order includes grace periods for different ...
As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...
Major pharmacy chains and a state regulatory agency said Friday that they’re continuing to work with the FDA on how to best ... of COVID-19,” said Dr. Patrizia Cavazzoni, director for the ...
AbbVie's CEO hinted his company may be less willing to invest in psychiatry, while Lilly explained what it got wrong forecasting GLP-1 drug demand.
The FDA recommended patients obtain drugs with "a prescription from their doctor and fill the prescription at a state-licensed pharmacy." Patrizia Cavazzoni, the director of the FDA’s Center for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback